Segall Bryant & Hamill LLC Sells 36,105 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Segall Bryant & Hamill LLC cut its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 2.4% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,490,376 shares of the biotechnology company’s stock after selling 36,105 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in BioCryst Pharmaceuticals were worth $11,327,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of BCRX. CWM LLC grew its stake in shares of BioCryst Pharmaceuticals by 200.0% during the 2nd quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 3,772 shares in the last quarter. Signaturefd LLC boosted its holdings in BioCryst Pharmaceuticals by 560.5% during the second quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 5,599 shares during the last quarter. Seven Eight Capital LP acquired a new position in BioCryst Pharmaceuticals during the first quarter worth $57,000. Mirae Asset Global Investments Co. Ltd. grew its position in BioCryst Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 1,322 shares in the last quarter. Finally, Natixis increased its stake in BioCryst Pharmaceuticals by 400.6% in the 1st quarter. Natixis now owns 11,684 shares of the biotechnology company’s stock valued at $59,000 after buying an additional 9,350 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. StockNews.com upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, August 6th. HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $14.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Royal Bank of Canada reissued an “outperform” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Finally, Barclays boosted their target price on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, BioCryst Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $15.60.

BioCryst Pharmaceuticals Trading Up 1.2 %

Shares of NASDAQ BCRX opened at $7.30 on Thursday. The company has a market capitalization of $1.51 billion, a P/E ratio of -11.97 and a beta of 1.89. BioCryst Pharmaceuticals, Inc. has a 12 month low of $4.03 and a 12 month high of $8.88. The stock has a 50 day moving average of $7.67 and a 200-day moving average of $7.20.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, meeting the consensus estimate of ($0.07). The company had revenue of $117.10 million during the quarter, compared to analyst estimates of $113.99 million. BioCryst Pharmaceuticals’s revenue for the quarter was up 35.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.19) earnings per share. Analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.38 EPS for the current fiscal year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.